12/12
11:49 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
12/12
11:45 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
11/15
08:04 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
Medium
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
11/15
08:04 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
Medium
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
11/15
05:15 am
bmrn
Rating for BMRN
Medium
Report
Rating for BMRN
11/15
05:15 am
bmrn
Rating for BMRN
Medium
Report
Rating for BMRN
11/14
04:12 pm
bmrn
BioMarin initiated with bullish view at Wolfe Research
Medium
Report
BioMarin initiated with bullish view at Wolfe Research
11/14
04:12 pm
bmrn
BioMarin initiated with bullish view at Wolfe Research
Medium
Report
BioMarin initiated with bullish view at Wolfe Research
11/6
06:32 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/6
06:32 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Wedbush to a "strong-buy" rating.
10/30
02:33 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
02:33 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
01:25 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
01:13 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
12:45 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
11:28 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
10/30
11:28 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $80.00 price target on the stock.
10/30
11:18 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
11:18 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
10:24 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
09:36 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
07:27 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
07:27 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/30
07:27 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
10/30
07:27 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.